BNP Paribas Financial Markets’s PDL BioPharma, Inc. PDLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-13,190
| Closed | – | – | 4469 |
|
|
2021
Q4 | $0 | Buy |
+13,190
| New | – | ﹤0.01% | 4332 |
|
|
2021
Q1 | – | Sell |
-13,190
| Closed | -$32.6K | – | 4261 |
|
|
2020
Q4 | $32.6K | Sell |
13,190
-19,391
| -60% | -$47.2K | ﹤0.01% | 3726 |
|
|
2020
Q3 | $103K | Buy |
32,581
+18,432
| +130% | +$58.9K | ﹤0.01% | 3100 |
|
|
2020
Q2 | $41.2K | Sell |
14,149
-23,338
| -62% | -$73.8K | ﹤0.01% | 3128 |
|
|
2020
Q1 | $106K | Buy |
37,487
+13,501
| +56% | +$43.5K | ﹤0.01% | 3179 |
|
|
2019
Q4 | $77.8K | Sell |
23,986
-1,696
| -7% | -$4.92K | ﹤0.01% | 3413 |
|
|
2019
Q3 | $55.5K | Buy |
25,682
+5,798
| +29% | +$15.5K | ﹤0.01% | 3417 |
|
|
2019
Q2 | $62.4K | Sell |
19,884
-14,321
| -42% | -$46.5K | ﹤0.01% | 3289 |
|
|
2019
Q1 | $127K | Buy |
34,205
+29,834
| +683% | +$101K | ﹤0.01% | 2978 |
|
|
2018
Q4 | $12.7K | Sell |
4,371
-5,296
| -55% | -$14.6K | ﹤0.01% | 3270 |
|
|
2018
Q3 | $25.4K | Sell |
9,667
-829
| -8% | -$2.04K | ﹤0.01% | 3316 |
|
|
2018
Q2 | $24.6K | Sell |
10,496
-32,579
| -76% | -$91K | ﹤0.01% | 3416 |
|
|
2018
Q1 | $127K | Sell |
43,075
-26,822
| -38% | -$73.2K | ﹤0.01% | 3074 |
|
|
2017
Q4 | $192K | Buy |
69,897
+16,313
| +30% | +$50.1K | ﹤0.01% | 2981 |
|
|
2017
Q3 | $182K | Buy |
53,584
+31,418
| +142% | +$87.4K | ﹤0.01% | 2505 |
|
|
2017
Q2 | $54.8K | Buy |
22,166
+18,478
| +501% | +$42.5K | ﹤0.01% | 3144 |
|
|
2017
Q1 | $8.37K | Sell |
3,688
-6,347
| -63% | -$14K | ﹤0.01% | 3201 |
|
|
2016
Q4 | $21.3K | Sell |
10,035
-7,929
| -44% | -$22.1K | ﹤0.01% | 3157 |
|
|
2016
Q3 | $60.2K | Buy |
17,964
+7,638
| +74% | +$24.2K | ﹤0.01% | 2350 |
|
|
2016
Q2 | $32.4K | Buy |
10,326
+9,977
| +2,859% | +$33.3K | ﹤0.01% | 2434 |
|
|
2016
Q1 | $1.16K | Sell |
349
-36,535
| -99% | -$114K | ﹤0.01% | 2491 |
|
|
2015
Q4 | $131K | Sell |
36,884
-126,333
| -77% | -$529K | ﹤0.01% | 2164 |
|
|
2015
Q3 | $821K | Buy |
163,217
+40,727
| +33% | +$233K | ﹤0.01% | 1110 |
|
|
2015
Q2 | $788K | Buy |
122,490
+116,640
| +1,994% | +$781K | ﹤0.01% | 1193 |
|
|
2015
Q1 | $41.2K | Sell |
5,850
-344,689
| -98% | -$2.5M | ﹤0.01% | 2016 |
|
|
2014
Q4 | $2.7M | Buy |
350,539
+67,045
| +24% | +$531K | 0.01% | 789 |
|
|
2014
Q3 | $2.12M | Sell |
283,494
-258,710
| -48% | -$2.4M | ﹤0.01% | 996 |
|
|
2014
Q2 | $5.25M | Buy |
542,204
+194,239
| +56% | +$1.73M | ﹤0.01% | 645 |
|
|
2014
Q1 | $2.95M | Buy |
347,965
+156,208
| +81% | +$1.34M | ﹤0.01% | 817 |
|
|
2013
Q4 | $1.62M | Buy |
191,757
+3,544
| +2% | +$29.9K | ﹤0.01% | 925 |
|
|
2013
Q3 | $1.5M | Buy |
188,213
+17,076
| +10% | +$137K | ﹤0.01% | 1012 |
|
|
2013
Q2 | $1.32M | Buy |
+171,137
| New | +$1.33M | ﹤0.01% | 885 |
|
Other funds holding PDLI
BNP Paribas Financial Markets's PDLI Position: Q1 2022 in Review
BNP Paribas Financial Markets sold out of PDL BioPharma, Inc. (PDLI) in Q1 2022, closing a stake of 13,190 shares.
BNP Paribas Financial Markets first reported a position in PDLI in Q2 2013 and held it in 32 quarters. The position peaked at $5.25M in Q2 2014. 5 funds tracked by Wall St. Rank hold PDLI as of Q1 2022.
- BNP Paribas Financial Markets reported no remaining PDL BioPharma, Inc. position as of Q1 2022 after selling out during the quarter.
- BNP Paribas Financial Markets sold 13,190 PDL BioPharma, Inc. shares in Q1 2022.
- BNP Paribas Financial Markets first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 32 quarters.
- BNP Paribas Financial Markets's PDL BioPharma, Inc. position peaked at $5.25M in Q2 2014.
- 5 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2022.
Based on BNP Paribas Financial Markets's 13F filing for Q1 2022, filed 17 May 2022.